MediMabBio
PrivateLast Round
Series B
Oct 24, 2025
Est. Valuation
$13.64M
Total Funding Raised
$38M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
MediMabBio is a biotechnology company that develops protein therapeutics, including therapeutic antibodies and fusion proteins, for the treatment of cancer and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting, Government Contracts
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
MediMabBio Comparables
Compare MediMabBio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Hummingbird Bioscience | 77% | |
| Synthekine | 76% | |
| Xencor, Inc. | 71% |
MediMabBio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Oct 24, 2025 | ||||
| Series A | Feb 1, 2021 | ||||
| Pre Seed | Feb 15, 2019 |
MediMabBio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Seoul Investment Partners | Series B |
| Hyundai Investment Partners | Series B |
| BNH INVESTMENT | Series A, Pre Seed, Series B |
| Smilegate Investment | Pre Seed, Series B, Series A |
| iM Investment Partners | Series B |
| KB Investment | Series B |
| Timefolio Asset Management | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 20, 2026
Monthly visitors increased 273% MoM, reaching 7.1K.
- Nov 10, 2025
Attended Cytokines 2025, a key conference on immune-mediated diseases.
MediMabBio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about MediMabBio's valuation, stock price, and market status.
Is MediMabBio a public or private company?
MediMabBio is a private company.
What is the current stock price of MediMabBio?
MediMabBio is a private company, so its shares have no public market price. Caplight tracks MediMabBio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is MediMabBio worth (valuation)?
MediMabBio's valuation is estimated at $13.6M based on funding round data.
Can I buy MediMabBio stock?
MediMabBio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was MediMabBio's last funding round?
MediMabBio's most recent funding round was Series B on October 24, 2025.
Who are the main investors in MediMabBio?
Key investors in MediMabBio include Hyundai Investment Partners, BNH INVESTMENT, Smilegate Investment, iM Investment Partners, KB Investment.
Will MediMabBio IPO soon?
No public IPO plans have been announced for MediMabBio.
How can I track MediMabBio secondary market activity?
Caplight tracks bids, offers, and trades in MediMabBio's shares on secondary markets.